false
0001826667
0001826667
2024-05-15
2024-05-15
0001826667
us-gaap:CommonStockMember
2024-05-15
2024-05-15
0001826667
us-gaap:WarrantMember
2024-05-15
2024-05-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
May 15, 2024
TRISALUS
LIFE SCIENCES, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
001-39813 |
85-3009869 |
(State or Other Jurisdiction of
Incorporation) |
(Commission
File
Number) |
(I.R.S. Employer Identification
No.) |
6272
W. 91st Ave., Westminster,
Colorado |
80031 |
(Address of principal executive offices) |
(Zip Code) |
(888)
321-5212
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name of each exchange
on which registered |
Common
Stock, $0.0001 par value per share |
|
TLSI |
|
Nasdaq
Global Market |
Warrants,
each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share |
|
TLSIW |
|
Nasdaq
Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 |
Results of Operations and Financial Condition. |
On May 15, 2024, TriSalus Life Sciences, Inc.
(the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended
March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein
by reference.
The information in this Item 2.02 of this Current
Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange
Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such
filing, except as shall be expressly set forth by specific references in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TriSalus
Life Sciences, Inc. |
|
|
|
By: |
/s/ Sean Murphy |
|
|
Sean Murphy |
|
|
Chief Financial Officer |
Dated: May 15, 2024
Exhibit 99.1
TriSalus Reports Q1 2024 Financial Results
and Business Update
| · | Reported revenues
of $6.5 million in 1Q24, up 116% compared to 1Q23 |
| · | Reported Gross
Margin of 85% in 1Q24 |
| · | Secured up to $50
million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives |
| · | Announced the appointment
of Liselotte Hyveled to the Board of Directors |
| · | Full year sales
growth expected to exceed 50% |
| · | Conference call
May 15th at 9:00 a.m. EDT |
DENVER – May 15, 2024 - TriSalus Life Sciences Inc., (Nasdaq:
TLSI), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
“I’m proud to highlight our strong start in the first
quarter of 2024 with 116% growth in revenues compared to the first quarter of 2023 and significantly improving our financial position
with our debt financing facility with OrbiMed.” said Mary Szela, Chief Executive Officer of TriSalus. “With our recent positive
developments in reimbursement, clinical data, and the dedication of our seasoned executive team, we’re confident in our ability
to execute our company-building strategy. Our objectives of achieving over 50% top-line revenue growth, advancing our pipeline, and strengthening
our operational foundations remain firmly on track.”
First Quarter 2024 and Subsequent Highlights
Secured up to $50 million of Debt Financing with OrbiMed to support
TriNav® Infusion System growth initiatives
In April, TriSalus announced the closing of a debt financing facility
with OrbiMed, a healthcare investment firm. Under the terms of the Credit Agreement with OrbiMed, the Company borrowed $25 million at
closing. In addition, an aggregate of up to an additional $25 million is available in two tranches at the Company’s option, subject
to the Company’s achievement of certain revenue thresholds.
The $25 million draw, along with cash and cash equivalents on hand
of $4 million at March 31, 2024, are expected to provide sufficient cash runway to fund the Company’s operations through the end
of 2024. Including our SEPA agreement and other existing sources of liquidity and assuming we achieve the revenue targets and borrow
the remaining $25 million of the debt financing, the Company expects to have sufficient cash runway to fund operations through the end
of 2025.
Liselotte Hyveled appointed to the Board of Directors
In May, TriSalus announced the appointment of Liselotte Hyveled to
its Board of Directors. Ms. Hyveled currently serves as the Chief Patient Officer at Novo Nordisk, where she is responsible for ensuring
the integration of patient needs and perspectives into the company’s decision-making processes and operations. She brings over
two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence.
Financial Results for Q1 2024
Revenue, all of which is from the sale of the TriNav® Infusion
System, was $6.5 million in the first quarter ended March 31, 2024. This amount represents growth of 116% compared to the first quarter
of 2023, primarily due to increased selling resources and continued market share increases.
Gross margins were 85% in the first quarter ended March 31, 2024,
versus 78% in the first quarter of 2023. The improvement is due to increased factory volumes and improved operations efficiency.
Operating losses were $11.7 million in the first quarter ended March
31, 2024 versus $10.1 million in the first quarter of 2023. Increased investment in sales and marketing, research and development, as
well as general and administrative costs associated with becoming a public company more than offset increased gross profit in 2024.
Net losses available to common stockholders were $13.2 million in
the first quarter ended March 31, 2024 versus $8.3 million in the first quarter of 2023. Net losses in 2024 include the impact of non-cash
related gains/(losses) on change in fair value of SEPA and warrant liabilities of $2.5 million and change in fair value of contingent
earnout liabilities of ($4.0) million. Net losses in 2023 include the impact of non-cash related gains/(losses) on equity issuance of
($1.5) million, extinguishment of tranche liabilities of $0.9 million and change in fair value of SEPA and warrant liabilities of $2.4
million.
Basic and diluted loss per share for the first quarter ended March
31, 2024, was $0.60 versus $0.57 per share in the first quarter of 2023.
Conference Call
The event will be webcast live on the investor relations section of
TriSalus’ website at https://investors.trisaluslifesci.com/news-events/events-presentations on May 15, 2024 at 9:00 a.m.
EDT. Following the conclusion of the event, a webcast replay will be available on the website for approximately 90 days. Interested parties
participating by phone will need to register using this online form. After registering for the webcast, dial-in details will be
provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology
company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic
tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage
investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™
(PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors
and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address
the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that
delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to
improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve
patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies
ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO)
clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and
systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are
commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune
dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation
that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X and LinkedIn.
Forward Looking Statements
Statements made in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied
by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential
benefits of the Company’s PEDD drug delivery technology and nelitolimod investigational immunotherapy, the Company’s ability
to achieve the revenue milestones under the credit facility, the Company’s expectations about its cash runway, and the Company’s
ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking
statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates,
including that future clinical results may not be consistent with patient data generated during the Company’s clinical trials,
the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies,
the risks associated with the credit facility, including the Company’s ability to remain in compliance with all its obligations
thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its
equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to
access additional financing under the credit facility, changes in expected or existing competition or market conditions, changes in the
regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company’s
filings with the Securities and Exchange Commission under the heading "Risk Factors." All forward-looking statements contained
in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates
as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist
after the date on which they were made except as required by law.
Financials
TriSalus Life Sciences
Condensed Consolidated Statement of Operations (unaudited, in thousands)
| |
Three Months Ended | |
| |
March 31, | |
| |
2024 | | |
2023 | |
Revenue | |
$ | 6,457 | | |
$ | 2,984 | |
Cost of goods sold | |
| 971 | | |
| 662 | |
Gross Profit | |
| 5,486 | | |
| 2,322 | |
Operating expenses: | |
| | | |
| | |
Research and development | |
| 5,857 | | |
| 5,642 | |
Sales and marketing | |
| 6,687 | | |
| 3,249 | |
General and administrative | |
| 4,627 | | |
| 3,552 | |
Loss from operations | |
| (11,685 | ) | |
| (10,121 | ) |
Other income (expense): | |
| | | |
| | |
Interest income | |
| 92 | | |
| 35 | |
Interest expense | |
| (3 | ) | |
| (5 | ) |
Loss on equity issuance | |
| | | |
| (1,465 | ) |
Extinguishment of tranche liability | |
| | | |
| 881 | |
Change in fair value of SEPA and warrant liabilities | |
| 2,521 | | |
| 2,421 | |
Change in fair value of contingent earnout liability | |
| (3,988 | ) | |
| | |
Other expense, net | |
| (153 | ) | |
| (19 | ) |
Loss before income taxes | |
| (13,216 | ) | |
| (8,273 | ) |
Income tax (expense) benefit | |
| (3 | ) | |
| 5 | |
Net loss available to common stockholders | |
$ | (13,219 | ) | |
$ | (8,268 | ) |
Deemed dividend related to Series B-2 preferred stock down round provision | |
| | | |
| (959 | ) |
Undeclared dividends on Series A preferred stock | |
| (801 | ) | |
| | |
Net loss attributable to common stockholders | |
$ | (14,020 | ) | |
$ | (9,227 | ) |
Net loss per common share, basic and diluted | |
$ | (0.60 | ) | |
$ | (0.57 | ) |
Weighted average common shares outstanding, basic and diluted | |
| 23,323,045 | | |
| 16,166,581 | |
TriSalus Life Sciences
Condensed Consolidated Balance Sheets (unaudited, in thousands)
| |
March 31, | | |
December 31, | |
| |
2024 | | |
2023 | |
Assets | |
(unaudited) | | |
| |
Assets | |
| | | |
| | |
Cash and cash equivalents | |
| 3,970 | | |
| 11,777 | |
Accounts receivable | |
| 4,277 | | |
| 3,554 | |
Inventory, net | |
| 2,913 | | |
| 2,545 | |
Prepaid expenses | |
| 2,031 | | |
| 2,986 | |
Total current assets | |
| 13,191 | | |
| 20,862 | |
Property and equipment, net | |
| 1,965 | | |
| 2,091 | |
Right-of-use assets | |
| 1,196 | | |
| 1,179 | |
Intangible assets, net | |
| 1,113 | | |
| 1,127 | |
Other assets | |
| 424 | | |
| 466 | |
Total assets | |
| 17,889 | | |
| 25,725 | |
Liabilities and Stockholders' Equity (Deficit) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Trade payables | |
| 2,348 | | |
| 3,391 | |
Accrued liabilities | |
| 11,423 | | |
| 10,556 | |
Short-term lease liabilities | |
| 363 | | |
| 351 | |
Other current liabilities | |
| 260 | | |
| 389 | |
Total current liabilities | |
| 14,394 | | |
| 14,687 | |
Long-term lease liabilities | |
| 1,218 | | |
| 1,244 | |
Contingent earnout liability | |
| 22,620 | | |
| 18,632 | |
Warrant and SEPA liabilities | |
| 14,580 | | |
| 17,100 | |
Total liabilities | |
| 52,812 | | |
| 51,663 | |
Stockholders' equity (deficit): | |
| | | |
| | |
Preferred Stock, Series A $0.0001 par value per share, $10.00 liquidation value per
share. Authorized 10,000,000 and 10,000,000 shares at March 31, 2024, and December 31, 2023, respectively; issued and outstanding,
4,015,002 and 4,015,002 shares at March 31, 2024 and December 31, 2023, respectively | |
| | | |
| | |
Common stock, $0.0001 par value per share. Authorized 400,000,000 and 400,000,000
shares at March 31, 2024 and December 31, 2023, respectively; issued and outstanding 26,758,272 and 26,413,213 shares at March 31,
2024 and December 31, 2023, respectively | |
| 2 | | |
| 2 | |
Additional paid-in capital | |
| 226,671 | | |
| 222,437 | |
Accumulated deficit | |
| (261,596 | ) | |
| (248,377 | ) |
Total stockholders' deficit | |
| (34,923 | ) | |
| (25,938 | ) |
Total liabilities and stockholders' deficit | |
| 17,889 | | |
| 25,725 | |
Contacts
For Media Inquiries:
Stephanie Jacobson
Argot Partners
610.420.3049
TriSalus@argotpartners.com
For Investor Inquiries:
James Young
SVP-Investor Relations/Treasurer
847.337.0655
james.young@trisaluslifesci.com
v3.24.1.1.u2
Cover
|
May 15, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 15, 2024
|
Entity File Number |
001-39813
|
Entity Registrant Name |
TRISALUS
LIFE SCIENCES, INC.
|
Entity Central Index Key |
0001826667
|
Entity Tax Identification Number |
85-3009869
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
6272
W. 91st Ave.
|
Entity Address, City or Town |
Westminster
|
Entity Address, State or Province |
CO
|
Entity Address, Postal Zip Code |
80031
|
City Area Code |
888
|
Local Phone Number |
321-5212
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value per share
|
Trading Symbol |
TLSI
|
Security Exchange Name |
NASDAQ
|
Warrant [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Warrants,
each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
|
Trading Symbol |
TLSIW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
TriSalus Life Sciences (NASDAQ:TLSIW)
Historical Stock Chart
From May 2024 to Jun 2024
TriSalus Life Sciences (NASDAQ:TLSIW)
Historical Stock Chart
From Jun 2023 to Jun 2024